Airsculpt Technologies Inc
NASDAQ:AIRS

Watchlist Manager
Airsculpt Technologies Inc Logo
Airsculpt Technologies Inc
NASDAQ:AIRS
Watchlist
Price: 2.9 USD -0.17%
Market Cap: $181.1m

Airsculpt Technologies Inc
Investor Relations

AirSculpt Technologies, Inc. operates as a blank check company. The company is headquartered in Miami Beach, Florida and currently employs 240 full-time employees. The company went IPO on 2021-10-29. The firm's activities are conducted through the Professional Associations and its wholly owned subsidiaries, which owns and operates the non-clinical assets and provide management services. The company offers patients a range of customized body contouring procedures, including fat removal and fat transfer. The firm also offers fat transfer procedures that uses the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its fat transfer procedures include Power Brazilian Butt Lift (BBL), a Brazilian butt lift procedure; Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. The firm also leverages AirSculpt TV, which allows viewers into procedure rooms to watch its surgeons use AirSculpt body contouring procedure. The company operates in approximately 16 centers across 13 states.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 7, 2025
AI Summary
Q3 2025

Revenue Miss: Q3 revenue came in at $35 million, a 17.8% decline from the prior year and below expectations, prompting a reduction in full-year revenue guidance.

Lower Guidance: 2025 revenue outlook was cut to approximately $153 million (from $160–170 million) and EBITDA guidance was reaffirmed at the low end ($16 million).

GLP-1 Opportunity: Management is emphasizing new services to address demand from GLP-1 users, including expanding skin tightening and piloting new skin excision procedures.

Cost Controls: Strong SG&A and cost discipline led to more than $3 million in annualized cost savings so far this year, helping offset revenue softness.

London Exit: The company closed its only unprofitable London center to focus resources on North America.

Leadership Transition: Michael Arthur will become CFO in January 2026, succeeding Dennis Dean after a transition period.

Key Financials
Revenue
$35 million
Cases
2,780
Average Revenue per Case
$12,587
Patients Using Financing
52%
Cost of Services (percentage of revenue)
42.5%
Customer Acquisition Cost per Case
$3,100
Adjusted EBITDA
$3 million
Adjusted EBITDA Margin
8.7%
Net Loss
$9.5 million
Cash
$5.4 million
Gross Debt Outstanding
$57.9 million
Leverage Ratio
3.04x
Cash Flow from Operations
use of cash of $225,000
Earnings Call Recording
Other Earnings Calls

Management

Dr. Aaron J. Rollins M.D.
Founder & Executive Chairman
No Bio Available
Mr. Dennis Dean CPA
Interim CEO & CFO
No Bio Available
Mr. Todd Magazine
Advisor
No Bio Available
Mr. Philip Bodie
Chief Accounting Officer
No Bio Available
Stephanie Evans Greene
Chief Marketing Officer
No Bio Available

Contacts

Address
FLORIDA
Miami Beach
400 Alton Road, Unit Th-103M, Unit Th-103m
Contacts